International Journal of Frontiers in Medicine, 2024, 6(8); doi: 10.25236/IJFM.2024.060805.
Xiang Qi1, Chuhuan Peng2, Luyan Song3
1School of Pharmaceutical Sciences, Liaoning University, Shenyang, China
2International Department, High School Attached to Jiangxi Normal University, Nanchang, China
3School of Nursing and Rehabilitation, Shandong University, Jinan, China
In this study, we investigated the key genes and pathways involved in the treatment of diseases in Cornus officinalis based on the molecular approach of traditional Chinese medicine network. Cornus officinalis is produced in large quantities, is inexpensive, has high nutritional value, and has the efficacy of tonifying the liver and kidney, fixing astringency and stopping sweating. There have been many studies on Cornus officinalis in the past, but most of them only analyze a few active components of Cornus officinalis for specific diseases, and do not comprehensively cover all of its active components. We used the TCMSP database to explore the active components of Cornus officinalis and the corresponding human target genes. Then we used the WebGestalt platform to analyze the KEGG, GO, and other enrichment of human target genes, to obtain the top 10 pathways in terms of enrichment rate to make a histogram and analyze the top three pathways. Then we used String database for protein-protein interaction network analysis to identify a complex network including 29 gene nodes and identify three core nodes corresponding to three core genes. The results showed that there are 20 active ingredients of Cornus officinalis, corresponding to 30 non-redundant human target genes. PPARG, PRKACA and NR3C1 are the three core genes associated with the biological effects of the active ingredients of Cornus officinalis. This study provides guidelines for the potential value of Cornus officinalis in the treatment of many types of diseases and its potential applications in the field of medicine.
Cornus officinalis, Active components, Database, Pathway
Xiang Qi, Chuhuan Peng, Luyan Song. Analysis of the active ingredients of Cornus officinalis based on the molecular pharmacology network. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 8: 28-43. https://doi.org/10.25236/IJFM.2024.060805.
[1] Gao, X., Liu, Y., An, Z., & Ni, J. (2021). Active components and pharmacological effects of Cornus officinalis: Literature review. Frontiers in pharmacology, 12, 633447.
[2] Czerwińska, M. E., & Melzig, M. F. (2018). Cornus mas and Cornus officinalis—Analogies and differences of two medicinal plants traditionally used. Frontiers in pharmacology, 9, 894.
[3] Huang, F., Guo, H., Wei, Y., Zhao, X., Chen, Y., Lin, Z., ... & Sun, P. (2021). In silico network analysis of ingredients of Cornus officinalis in osteoporosis. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 27, e929219-1.
[4] Liu, P., Yang, P., & Zhang, L. (2020). Mode of action of Shan‐Zhu‐Yu (Cornus officinalis Sieb. Et Zucc.) in the treatment of depression based on network pharmacology. Evidence‐Based Complementary and Alternative Medicine, 2020(1), 8838888.
[5] Qu, Y. J., Zhen, R. R., Zhang, L. M., Gu, C., Chen, L., Peng, X., ... & An, H. M. (2020). Uncovering the active compounds and effective mechanisms of the dried mature sarcocarp of Cornus officinalis Sieb. Et Zucc. For the treatment of Alzheimer’s disease through a network pharmacology approach. BMC Complementary Medicine and Therapies, 20, 1-12.
[6] Ru, J., Li, P., Wang, J., Zhou, W., Li, B., Huang, C., ... & Yang, L. (2014). TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of cheminformatics, 6, 1-6.
[7] Elizarraras, J. M., Liao, Y., Shi, Z., Zhu, Q., Pico, A. R., & Zhang, B. (2024). WebGestalt 2024: faster gene set analysis and new support for metabolomics and multi-omics. Nucleic Acids Research, gkae456.
[8] Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., ... & Von Mering, C. (2023). The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic acids research, 51(D1), D638-D646.
[9] Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., ... & Lancet, D. (2016). The GeneCards suite: from gene data mining to disease genome sequence analyses. Current protocols in bioinformatics, 54(1), 1-30.
[10] Li, X. (2007). Extraction, isolation and pharmacokinetics of the active components of Cornus officinalis [D]. Hebei Medical University, 6, 1-173.
[11] Wu, J., Peng, Z., He, J., et al. (2024). A new cleavage ring enol ether terpenoid from Cornus officinalis [J]. Chinese Journal of Traditional Chinese Medicine, 1-7
[12] Liao, Y., Zhao, K., Guo, H. (2024). Research applications and challenges in network pharmacology of traditional Chinese medicine [J]. Chinese Herbal Medicine, 55(12), 4204-4213.
[13] Zhuang, Y., Cai, B., Zhang, Z. (2021). Progress in the application of network pharmacology in traditional Chinese medicine research [J]. Journal of Nanjing University of Traditional Chinese Medicine, 37(1), 156-160.
[14] Li, J., Wang, J., Yan, L., et al. (2024). Exploring the mechanism of action of Liuweidihuangwan heteropathic concomitant treatment of senile deafness and Alzheimer's disease based on network pharmacology and molecular docking [J]. Shanghai Journal of Traditional Chinese Medicine, 58(06), 23-30+39.
[15] Liao, Y., Wang, J. Y., Pan, Y., Zou, X., Wang, C., Peng, Y., ... & Zhang, S. (2023). The Protective Effect of (-)-Tetrahydroalstonine against OGD/R-Induced Neuronal Injury via Autophagy Regulation. Molecules, 28(5), 2370.
[16] Shen, Y., Cai, H., Ma, S., Zhu, W., Zhao, H., Li, J., ... & Xiao, Z. (2022). Telocinobufagin has antitumor effects in non-small-cell lung cancer by inhibiting STAT3 signaling. Journal of Natural Products, 85(4), 765-775.
[17] Chen, Q., Yang, G., Pan, Y. (2016). Progress in the extraction and isolation of functional components and bioactivity of Cornus officinalis [J]. Jiangsu Traditional Chinese Medicine, 48(01), 82-85.
[18] Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999). The cholinergic hypothesis of Alzheimer’s disease: a review of progress. Journal of Neurology, Neurosurgery & Psychiatry, 66(2), 137-147.
[19] Bartus, R. T., Dean III, R. L., Beer, B., & Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217(4558), 408-414.
[20] Yang, K., Li, L., Li, Z., et al. (2024). Study on the protective effect of Cornus officinalis alcohol extract modulating LSD1/PSD95 on Aβ_(25-35)-induced neurological injury in Alzheimer's disease mice [J]. Journal of Beijing University of Chinese Medicine, 47(03), 352-363.
[21] Li, D. H., Liu, X. K., Tian, X. T., Liu, F., Yao, X. J., & Dong, J. F. (2023). PPARG: a promising therapeutic target in breast cancer and regulation by natural drugs. PPAR research, 2023(1), 4481354.
[22] Furth, P. A. (2019). Peroxisome proliferator-activated receptor gamma and BRCA1. Endocrine-related cancer, 26(2), R73-R79.
[23] Toyota, A., Goto, M., Miyamoto, M., Nagashima, Y., Iwasaki, S., Komatsu, T., ... & Kaneta, Y. (2022). Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model. Biochemical and Biophysical Research Communications, 621, 157-161.
[24] Nascimento, M., Teixeira, E. S., Dal’Bó, I. F., Peres, K. C., Rabi, L. T., Cury, A. N., ... & Ward, L. S. (2023). NR3C1 rs6198 Variant May Be Involved in the Relationship of Graves’ Disease with Stressful Events. Biomedicines, 11(4), 1155.
[25] Kolb, K. L., Mira, A. L. S., Auer, E. D., Bucco, I. D. O., de Lima e Silva, C. E., Dos Santos, P. I., ... & Boldt, A. B. W. (2023). Glucocorticoid Receptor Gene (NR3C1) Polymorphisms and Metabolic Syndrome: Insights from the Mennonite Population. Genes, 14(9), 1805.